IAVI
United States
5 articles about IAVI
-
ReiThera Srl, The Ragon Institute and IAVI Announce Collaboration to Advance Highly Networked T Cell HIV Vaccine Candidate Towards Phase I Clinical Evaluation
1/22/2024
ReiThera Srl, the Ragon Institute of Mass General, MIT, and Harvard, and IAVI are pleased to announce a collaboration to develop a novel HIV vaccine candidate that will be composed of ReiThera’s GRAd vector and HIV T cell epitopes identified by the Ragon Institute, funded by the Bill & Melinda Gates Foundation.
-
The partnership framework agreement allows Moderna and U of T to collaborate across a broad variety of areas, ranging from molecular genetics to biomedical engineering, biochemistry and more.
-
Building on the success of its COVID-19 mRNA vaccine, Moderna, Inc. is partnering with the nonprofit scientific research organization IAVI to develop treatments and vaccines against global health threats.
-
IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies
4/7/2022
Moderna, Inc. today announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats.
-
Spanish pharmaceutical company Zendal and IAVI partner to advance the tuberculosis vaccine candidate MTBVAC into efficacy trials
7/14/2021
Biofabri and IAVI today announced their intention to partner on efficacy trials of the tuberculosis (TB) vaccine candidate MTBVAC.